- Home
- TLN vs INCY Comparison
TLN vs INCY Comparison
Compare TLN & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TLN | INCY |
|---|---|---|
| Founded | 2015 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 17.0B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | TLN | INCY |
|---|---|---|
| Price | $370.82 | $101.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 21 |
| Target Price | ★ $435.25 | $100.58 |
| AVG Volume (30 Days) | 1.1M | ★ 2.0M |
| Earning Date | 02-26-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | 4.55 | ★ 6.41 |
| Revenue | $2,343,000,000.00 | ★ $5,141,242,000.00 |
| Revenue This Year | $17.17 | $9.49 |
| Revenue Next Year | $72.33 | $9.88 |
| P/E Ratio | $77.87 | ★ $15.42 |
| Revenue Growth | 16.22 | ★ 21.22 |
| 52 Week Low | $158.08 | $53.56 |
| 52 Week High | $451.28 | $112.29 |
Technical Indicators
Market Signals| Indicator | TLN | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 53.53 | 48.18 |
| Support Level | $334.00 | $97.25 |
| Resistance Level | $366.85 | $109.71 |
| Average True Range (ATR) | 18.71 | 3.53 |
| MACD | 2.11 | -0.31 |
| Stochastic Oscillator | 95.45 | 35.44 |
Price Performance
Historical ComparisonAbout TLN Talen Energy Corporation
Talen Energy Corp is an independent power producer and energy infrastructure company. The company owns and operates approximately 10.7 gigawatts of power infrastructure in the United States. The group produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, including PJM and WECC, with its generation fleet located in the Mid-Atlantic and Montana.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.